On the feasibility of using TCR sequencing to follow a vaccination response - lessons learned

Front Immunol. 2023 Jul 13:14:1210168. doi: 10.3389/fimmu.2023.1210168. eCollection 2023.

Abstract

T cells recognize pathogens by their highly specific T-cell receptor (TCR), which can bind small fragments of an antigen presented on the Major Histocompatibility Complex (MHC). Antigens that are provided through vaccination cause specific T cells to respond by expanding and forming specific memory to combat a future infection. Quantification of this T-cell response could improve vaccine monitoring or identify individuals with a reduced ability to respond to a vaccination. In this proof-of-concept study we use longitudinal sequencing of the TCRβ repertoire to quantify the response in the CD4+ memory T-cell pool upon pneumococcal conjugate vaccination. This comes with several challenges owing to the enormous size and diversity of the T-cell pool, the limited frequency of vaccine-specific TCRs in the total repertoire, and the variation in sample size and quality. We defined quantitative requirements to classify T-cell expansions and identified critical parameters that aid in reliable analysis of the data. In the context of pneumococcal conjugate vaccination, we were able to detect robust T-cell expansions in a minority of the donors, which suggests that the T-cell response against the conjugate in the pneumococcal vaccine is small and/or very broad. These results indicate that there is still a long way to go before TCR sequencing can be reliably used as a personal biomarker for vaccine-induced protection. Nevertheless, this study highlights the importance of having multiple samples containing sufficient T-cell numbers, which will support future studies that characterize T-cell responses using longitudinal TCR sequencing.

Keywords: TCR - T cell receptor; high-throughput sequencing; immune response; pneumococcal 13-valent polysaccharide vaccine; vaccination.

MeSH terms

  • CD4-Positive T-Lymphocytes
  • Feasibility Studies
  • Humans
  • Receptors, Antigen, T-Cell* / genetics
  • Vaccination*

Substances

  • Receptors, Antigen, T-Cell

Grants and funding

This work was supported by The Netherlands Organization for Scientific Research, NWA Idea Generator 2019 1228.192.044 (to JL), and Graduate Program 022.005.023 (to PG). The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 806776 and the Dutch Ministry of Health, Welfare and Sport. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA-members.